XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

This study is testing a personalized cancer vaccine called XP-005 — alone or combined with an immunotherapy drug (toripalimab) — in people with acute myeloid leukemia (AML, a type of blood cancer) who are in remission but still have detectable traces of cancer. The vaccine is tailored to the patient's specific cancer mutations to help the immune system find and eliminate remaining cancer cells. **You may be eligible if...** - You are 18 or older with a confirmed AML diagnosis - You have completed chemotherapy and reached remission, but still have measurable residual disease (traces of cancer detectable by specialized lab tests) - You are not suitable for, or do not want, a stem cell transplant - Your expected survival is at least 3 months and your organ function is adequate **You may NOT be eligible if...** - You have already received a stem cell transplant - You currently have active infections like HIV, hepatitis B, or tuberculosis that are not controlled - You have other active cancers at the time of enrollment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.